{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:32:37Z","timestamp":1791232357289,"version":"4.1.0"},"reference-count":62,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Intern Med"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The development of disease\u2010modifying therapies (DMTs) for Alzheimer's disease (AD) has progressed over the last decade, and the first\u2010ever therapies with potential to slow the progression of disease are approved in the United States. AD DMTs could provide life\u2010changing opportunities for people living with this disease, as well as for their caregivers. They could also ease some of the immense societal and economic burden of dementia. However, AD DMTs also come with major challenges due to the large unmet medical need, high prevalence of AD, new costs related to diagnosis, treatment and monitoring, and uncertainty in the therapies\u2019 actual clinical value. This perspective article discusses, from the broad perspective of various health systems and stakeholders, how we can overcome these challenges and improve society's readiness for AD DMTs. We propose that innovative payment models such as performance\u2010based payments, in combination with learning healthcare systems, could be the way forward to enable timely patient access to treatments, improve accuracy of cost\u2010effectiveness evaluations and overcome budgetary barriers. Other important considerations include the need for identification of key drivers of patient value, the relevance of different economic perspectives (i.e. healthcare vs. societal) and ethical questions in terms of treatment eligibility criteria.<\/jats:p>","DOI":"10.1111\/joim.13759","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T05:20:39Z","timestamp":1702617639000},"page":"281-291","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare"],"prefix":"10.1111","volume":"295","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0613-0212","authenticated-orcid":false,"given":"Karin","family":"Wahlberg","sequence":"first","affiliation":[{"name":"The Swedish Institute for Health Economics  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-1179","authenticated-orcid":false,"given":"Bengt","family":"Winblad","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Karolinska Institutet  Solna Sweden"},{"name":"Theme Inflammation and Aging Karolinska University Hospital  Huddinge Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Cole","sequence":"additional","affiliation":[{"name":"Office of Health Economics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Herring","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Karolinska Institutet  Solna Sweden"},{"name":"RTI Health Solutions  Research Triangle Park North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Ramsberg","sequence":"additional","affiliation":[{"name":"The Swedish Brain Foundation  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Torontali","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter\u2010Jelle","family":"Visser","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Karolinska Institutet  Solna Sweden"},{"name":"Alzheimer Center Amsterdam Vrije Universiteit Amsterdam, Amsterdam UMC  Amsterdam The Netherlands"},{"name":"Amsterdam Neuroscience, Neurodegeneration  Amsterdam The Netherlands"},{"name":"Department of Psychiatry Maastricht University  Maastricht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Wimo","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Karolinska Institutet  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Wollaert","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[{"name":"Division of Neurogeriatrics Department of Neurobiology Care Sciences and Society, Karolinska Institutet  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization.Global status report on the public health response to dementia.Geneva:WHO;2021."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12901"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12694"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13244"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245789"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180802"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225536"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207443"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X18666200528142429"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12295"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2017.05.002"},{"key":"e_1_2_10_14_1","unstructured":"US Food and Drug Administration (FDA).FDA grants accelerated approval for Alzheimer's disease treatment [FDA news release 6 Jan 2023].FDA Silver Spring MD;2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010grants\u2010accelerated\u2010approval\u2010alzheimers\u2010disease\u2010treatment"},{"key":"e_1_2_10_15_1","unstructured":"US Food and Drug Administration (FDA).FDA's decision to approve new treatment for Alzheimer's disease.FDA Silver Spring MD;2021.https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fdas\u2010decision\u2010approve\u2010new\u2010treatment\u2010alzheimers\u2010disease"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_10_17_1","unstructured":"US Food and Drug Administration (FDA).FDA converts novel Alzheimer's disease treatment to traditional approval [FDA news release 6 July 2023].FDA Silver spring MD;2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010converts\u2010novel\u2010alzheimers\u2010disease\u2010treatment\u2010traditional\u2010approval"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_10_19_1","unstructured":"Eli Lilly and Company.Results from Lilly's landmark phase 3 trial of donanemab presented at Alzheimer's Association conference and published in JAMA.2023 July 17.https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/results\u2010lillys\u2010landmark\u2010phase\u20103\u2010trial\u2010donanemab\u2010presented. Accessed 17 Jul 2023."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12213"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210736"},{"key":"e_1_2_10_22_1","unstructured":"LinGA WhittingtonMD WrightA AgboolaF Herron\u2010SmithS PearsonSD et\u00a0al.Lecanemab for early Alzheimer's disease[final evidence report].Institute for Clinical and Economic Review (ICER) Boston MA; April 17 2023."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2022.06.012"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2016.06.002"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12698"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1927747"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1822738"},{"key":"e_1_2_10_29_1","first-page":"7","article-title":"Defining elements of value in Alzheimer's disease","volume":"2","author":"Garrison LP","year":"2021","journal-title":"Value & Outcomes Spotlight."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-190426"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00445-0"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00443-2"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00984-y"},{"key":"e_1_2_10_34_1","unstructured":"SveDem.The Swedish registry for cognitive\/dementia disorders.https:\/\/www.ucr.uu.se\/svedem\/. Accessed 15 Jul 2023."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116538"},{"key":"e_1_2_10_36_1","unstructured":"BNA (French Alzheimer Bank).http:\/\/www.banque\u2010nationale\u2010alzheimer.fr\/csp\/bna2\u2010public\/Kanope.Modules.Bna.Pages.home.zen. Accessed 26 May 2023."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029663"},{"key":"e_1_2_10_38_1","unstructured":"The Centers for Medicare & Medicaid Services (CMS).CMS announces new details of plan to cover new Alzheimer's drugs.2023.https:\/\/www.cms.gov\/newsroom\/fact\u2010sheets\/cms\u2010announces\u2010new\u2010details\u2010plan\u2010cover\u2010new\u2010alzheimers\u2010drugs. Accessed 17 Oct 2023."},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29392"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.09.008"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00460-1"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12159"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.06.003"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.17925\/USN.2023.19.1.14"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.007"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_2_10_47_1","unstructured":"WenzlM ChapmanS.Performance\u2010based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward.OECD health working papers.Paris:OECD Publishing;2019."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.04.011"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01150-w"},{"key":"e_1_2_10_50_1","unstructured":"ColeA TowseA.Legal barriers to the better use of health data to deliver pharmaceutical innovation [OHE contract research].Office of Health Economics OHE London;2018. Available fromhttps:\/\/www.ohe.org\/publications\/legal-barriers-better-use-health-data-deliver-pharmaceutical-innovation\/"},{"key":"e_1_2_10_51_1","unstructured":"ColeA Cubi\u2010MollaP ElliottR FeastA HockingL LorgellyP et\u00a0al.Making outcome\u2010based payment a reality in the NHS. Phase two: Practical considerations [OHE Grant\u2010Funded Research].Office of Health Economics OHE London;2021."},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00350-y"},{"key":"e_1_2_10_53_1","first-page":"371","article-title":"Diagnosis of early Alzheimer's disease: clinical practice in 2021","volume":"8","author":"Porsteinsson AP","year":"2021","journal-title":"J Prev Alzheimers Dis."},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071760"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.2196\/12785"},{"key":"e_1_2_10_57_1","first-page":"1","article-title":"Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda","volume":"14","author":"Kumar Y","year":"2022","journal-title":"J Ambient Intell Humaniz Comput."},{"key":"e_1_2_10_58_1","first-page":"2","article-title":"Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment","volume":"8","author":"Hlavka JP","year":"2019","journal-title":"Rand Health Q."},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2021-107304"},{"key":"e_1_2_10_60_1","unstructured":"European Federation of Pharmaceutical Industries and Associations (EFPIA).Alzheimer's disease health system readiness \u2013 the time to act is now.Brussels:EFPIA;2020.https:\/\/www.efpia.eu\/media\/554727\/efpia\u2010ad\u2010platform\u2010health\u2010system\u2010readiness.pdf"},{"key":"e_1_2_10_61_1","unstructured":"Agency for Healthcare Research and Quality (AHRQ).About learning health systems.AHRQ Rockville MD;2019.https:\/\/www.ahrq.gov\/learning\u2010health\u2010systems\/about.html"},{"key":"e_1_2_10_62_1","volume-title":"The learning healthcare system: Workshop summary","author":"Institute of Medicine (US) Roundtable on Evidence\u2010Based Medicine","year":"2007"},{"key":"e_1_2_10_63_1","unstructured":"ROADMAP \u2013 Real World Outcomes across the AD Spectrum for better care.https:\/\/roadmap\u2010alzheimer.org\/project\/structure\/Accessed 17 Oct 2023."}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/joim.13759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T09:49:47Z","timestamp":1707817787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/joim.13759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/joim.13759"],"URL":"https:\/\/doi.org\/10.1111\/joim.13759","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"value":"0954-6820","type":"print"},{"value":"1365-2796","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"2023-12-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}